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 Supplementary Figure 1. PfEBA165 full alignment. 
Exemplar EBA165 amino acid sequences (~800 bp amplified fragment) from ape-infective 
Laverania species (G1, Plasmodium praefalciparum; G2, P. adleri; G3, P. blacklocki; C1, P. 
reichenowi; C2, P gaboni; C3, P. billcollinsi; B1, P. lomamiensis) as recently described 3. 
The 3D7 P. falciparum sequence shown is that which would be translated if both frameshifts 
were corrected, and represents the relevant fragment of the full-length corrected PfEBA165 
protein ectodomain that was expressed recombinantly. 
 
 
Alignment: newfile
Seaview [blocks=80 fontsize=10 A4] on Thu Sep 27 12:15:57 2018
    1
Pf  ALCKLENYIKNEYDRENSFYILNNKVEKEYEKGT-NNNINIDKLANGSLEMLDK-KEALLEDKKNVDNKDIKEQLPENNK
G1  ALCKLENYIKNEYDRENSFYILNNKVEKEYEKGT-NNNINIDKLANGSLEMLEVKKEALLEDKKNVDNKDIKEQLPEHNK
G2  TLCKLENYLKNEYEKENSFNIINNKVEKEYDSGT-NNNVNIDSSSNGKLELLEVKEDALLND------KNIQEQEAENNI
C1  ALCKLENYIKNEYDKENSVYIINNKVEKDYGSGMNNNNINIDKLPNGSLEILKVKKEALLGDKKNIDNKDIKEQLPENNK
C2  TLCKLENYLKNEYEKENSFNIINNKVVKEYDSGT-NNNVNIDRSSNGRLELLEVKEEALLND------KNIEEEEAENNI
C3  TLCKLENNIKNKYDKENSFYIINNKVEKAYEGGT-NNNINIDKLSNGSLEMLEVKEETLFDDKKNIHNKDIKEQLTENNI
B1  ALCKLENYIKNEYES-----------------GM-NNNINIDKLPNGSLEILKVKKEALLGDKKNIDNKDIKEQLPENNK
   81
Pf  NFEEKILHEDICKLNKENIEKEGLYKPNTFKSIGNDLLYKKGKLNFLYEYGMELLHINKVPMNRMNNSRGLGDSNMSFLD
G1  NFEEKILYEDICKLNKENIEKEGLYKPNTFKSIGNDLLYKKGKLNFLYEYGMELLHINKVPMNRMNNSRGLGDSNMSFLD
G2  NFEEKILHKNVYELNKESIEKEGLYKPNTIKNIEDESLYKKGKLNFLYEYGMELLNINKVRMNKMNNSRGLGDSNTSFLD
C1  NFEEKILHKDICKLNKENIEKEGLYKPNTFKNIENDLLYKKGKLNFLYDYGMELLHINKAPMNRMNNSRGLGDGDMSFLD
C2  NFEEKILYKNVCELNKENIEKEGLYKPNTIKNIENDSLYKKGMLNFLYEYGMELLNINKVPMNKMNNSRVLGDSKMSFLD
C3  NYEEKNLLKDICILNKEKIEKEGLYKPSTFKYIENDSLYKKGKLNFLYVYGMELLHINKTSMNRMNNFRVLGDSNMSYLD
B1  NFEEKILHKDICKLNKENIENEGLYKPNTFKNIENDLLYKKGKLNFLYEYGMELLHINKARMNRMNNSRGLGDSNMSFLD
  161
Pf  ISNNNMNSLNSM---NNLNNSNNFDSSNSLSFVDMKSIHRCIKKRAKGERDWACNDKNTKEPNICVSDRRVQLCTGNLIE
G1  ISNNNMNSLNNLNNLNNLNNSNNFDSSNSLSFVDMKSIHRCIKKRAKGERDWACNDKNTKEPNICVSDRRVQLCTGNLIE
G2  ISNNNNKN-----------KNNNMNNLNSLSFVDMKSVHRCITKRKKGEKDWACNDKNTKEPNICVSDRRVQLCTGNLVD
C1  ISNNNMNISNSL------------DSLNSLSFVDMKSIHRCIKKRAKGERDWVCNNKNTKEPNICVSDRKVQLCTGNLIE
C2  ISNNNNKN-----------KNNNMNNLNSLSFVDMKSIHRCITKRKKGEKDWACNDKNTKEPNICVSDRRVQLCTGNLVD
C3  ISNNTNN--NNMNSLNSSNNLNNMNSFNSLSFVDMKFLHRCIKKRNKGERDWKCNDINTKEPNICVSDRRVQLCTGNLID
B1  ISNNNMNILNSVDN---------LDSLNSLSFVDMKSIHRCIKKRAKGERDWVCNNKNTKEPNVCVSDRKVQLCTGNLIE
  241
Pf  LPINDSTKEKFKEKLILAAQKEGSLLFEKFGKKYNEEFCLNLKWSYGDYGDIIK
G1  LPINDSTKDKFKEKLILAAQKEGSLLFEKFGKKYNEEFCLNLKWSYGDYGDIIK
G2  LSIDESTKEKFKEKLIIAAKREGTLLFEKFGKEYTAEFCLNLKWSYSDYGDIIK
C1  LPISDSTKEKFKEKLILAAQKEGSLLFEKFGKKYNEEFCLNLKWSYGDYGDIIK
C2  LSINDATKEKFEGKLIIAAKREGTLLFEKFGKKYTAEFCLNLKWSYSDYGDIIK
C3  IPTNESTKEKFKEKLILAAKREGSLLFEKFGKIYNAEFCLNLKWSYSDYGDIIK
B1  LPISDSTKEKFKEKLILAAEKEGNLLFEKFGKKYNEEFCLNLKWSYGDYGDIIK
 Supplementary Figure 2. PfEBA165, PrEBA165 and PfEBA175 bind primarily sialic 
acid containing glycans 
Purified mono-biotinylated glycans (GlycoTech) were immobilised on streptavidin-coated 96 
well plates and probed with normalised recombinant pentameric β-lactamase-tagged 
PfEBA165, PrEBA165 and PfEBA175 (black, grey, and white bars, respectively). Binding 
was detected by incubation with nitrocefin, a substrate for β-lactamase. As expected from 
the known binding specificity of PfEBA175, most binding was detected with glycans 
containing sialic acids. Data points represent mean values of three technical replicates, 
conducted on the same batches of recombinant proteins and glycans. 
  
 Supplementary Figure 3. CMAH expression has no impact on surface levels of major 
erythrocyte receptors. 
Surface expression of Basigin (BSG), Glycophorin C (GPC), Glycophorin A (GPA), CD71, 
Duffy Antigen Receptor for Chemokines (DARC) was measured by incubating cultured red 
blood cells (cRBCs) or human red blood cells (RBCs) with either commercial monoclonal 
antibodies followed by fluorescently tagged secondary antibodies (BSG and Neu5Gc), or 
primary antibodies directly conjugated to fluorophores (DARC, CD71, GPA, GPC), with 
binding detected by flow cytometry (blue traces). Secondary antibodies alone were used as 
a negative control for binding (red traces). There was no detectable difference in the surface 
expression of known P. falciparum invasion receptors (BSG, GPA, GPC) between cRBCs 
produced from hSCs transfected with control (pLVX) or CMAH expressing vectors. cRBCs 
expressed higher levels of CD71 and lower levels of DARC compared to human RBCs, as 
has been previously shown with the cRBC expression system, thought to reflect the fact that 
cRBCs represent more immature RBCs1,2. Expression of CMAH resulted in Neu5Gc 
expression on the cRBC surface. NeuGc is present in primate erythrocytes such as ape and 
macaque (shown), but not on human erythrocytes or control cRBCs. 
  
 
Supplementary Figure 4. Genome editing of PfEBA165 to correct frameshift mutations 
has no impact on erythrocyte invasion profile or in vitro growth rate. 
A) Relative growth of P. falciparum 3D7 (parental), YB4 (cloned transfectant with 1 
frameshift corrected) and C10 and D3 (cloned transfectant lines with both frameshifts 
corrected) lines during continuous culture in human erythrocytes. Lines were diluted with 
fresh red blood cells every two days, parasitaemia counted using flow cytometry, and 
cumulative parasitaemia calculated adjusting for the dilution factors. There was no difference 
in growth rates between the lines. Data points represents mean values of three biological 
replicates. Error bars represent standard deviation. 
B) Invasion of P. falciparum 3D7 (parental), and C10 and D3 (cloned transfectant lines with 
both frameshifts corrected) into human erythrocytes that were either untreated (u), or treated 
with neuraminidase (NM) to remove surface sialic acids. Erythrocytes were labelled with 
fluorescent dyes, and new invasion events were identified using a two-colour flow cytometry 
assay3. Two separate assays were conducted (expt 1 and expt 2). Invasion rates are 
expressed relative to the invasion into untreated human erythrocytes of each strain in 
separate experiments. Bars represent mean values of four technical replicates for expt 1 and 
three technical replicates for expt 2, with individual data points overlaid as black circles. 
Error bars represent standard deviation.  
C) Invasion of P. falciparum 3D7 (parental), and C10 and D3 (cloned transfectant lines with 
both frameshifts corrected) into chimpanzee erythrocytes that were either untreated (u), or 
treated with neuraminidase (NM) to remove surface sialic acids. Erythrocytes were labelled 
with fluorescent dyes, and new invasion events were identified using a two-colour flow 
cytometry assay3. Invasion rates are expressed relative to the invasion into untreated 
chimpanzee erythrocytes of each strain. Bars represent mean values of four technical 
replicates from one assay, with individual data points overlaid as black circles. Error bars 
represent standard deviation. 
D) P. falciparum 3D7 (parental), and C10 and D3 (cloned transfectant lines with both 
frameshifts corrected) lines were incubated with enzyme treated erythrocytes for 24 hours, 
and invasion measured using two-colour flow cytometry to count invasion only into treated 
erythrocytes. Data points represent mean values of three technical replicates from a single 
assay. Error bars represent standard deviation. Invasion rates are expressed relative to 
invasion into untreated erythrocytes for each parasite line.  
 
 
 
 
 
 
 
Supplementary Figure 5. Flow cytometry gating strategy for erythrocyte binding 
assays.  
Gates were determined using control samples with cells only. Cells were selected using 
gates P1 (side scatter-area (SSC-A) vs forward scatter-area (FSC-A)), P2 (forward scatter-
width (FSC-W) and forward scatter-area (FSC-A)), and P3 (forward scatter-area (FSC-A) 
and phycoerthrin-area (PE-A)).   
Supplementary Table 1. Significantly down-regulated genes in PfEBA165 corrected 
lines.
 
Significantly down-regulated gene clusters in PfEBA165 corrected lines (double-edited 
clones C10 and D3). Genes that are significantly down-regulated (p-value ≤ 0.05) in both 
C10 and D3 relative to the parent line 3D7 in the order are listed in which they appear along 
the two down-regulated clusters of genes located on chromosomes 4 and 11, respectively. 
 
  
Table 1. Significantly differentially expressed gene regions in double-edited clones C10 and D3 
GeneID Gene description
Log2FC
C10
p-value
C10
Log2FC
D3
p-value
D3
Pf3D7_0424200 Reticulocyte binding protein 
homologue (Rh4)
-1.03 3.32E-42 NA NA
Pf3D7_0424300 Erythrocyte binding antigen 165 
(EBA165)
-2.20 8.33E-137 -2.18 3.41E-78
Pf3D7_0424400 Surface-associated interspersed 
protein 4.2 (SURFIN 4.2)
-1.28 0.028 -1.78 0.003
Pf3D7_0424500 Serine/threonine protein kinase,
FIKK family
-1.25 3.33E-14 -1.23 3.48E-10
Pf3D7_0424600 Plasmodium exported protein 
(PHISTb, unknown function)
-0.89 2.87E-26 -0.69 0.001
Pf3D7_0424700 Serine/threonine protein kinase, 
FIKK family
-0.65 7.81E-05 -1.44 1.16E-10
Pf3D7_0424800 Plasmodium exported protein 
(PHISTa, unknown function)
-2.27 0.0007 -1.84 0.003
Pf3D7_0424900 Plasmodium exported protein 
(PHISTb, unknown function)
-1.18 8.08E-08 -1.64 1.08E-08
Pf3D7_1147000 Sporozoite and liver stage 
asparagine-rich protein (SLARP)
-6.29 9.31E-234 -6.62 1.13E-159
Pf3D7_1147100 Dynein light chain, putative -3.69 0.0006 -3.44 0.0004
Pf3D7_1147200 Tubulin tyrosine ligase,putative -3.74 2.43E-110 -3.16 2.87E-54
Supplementary Table 2. Oligonucleotides used in this study  
 
 
Oligo Description Gene name Gene ID 5' to 3' sequence 
OL176 gRNA 5' frameshift.  Anneal to OL177. PfEAB165 PF3D7_0424300 ATTGATAAGTTGGCAAATGGGAGTT 
OL177 gRNA 5' frameshift.  Anneal to OL176 PfEAB165 PF3D7_0424300 AAACAACTCCCATTTGCCAACTTAT 
OL186 
Phosphorothoiate modified 
oligo. Product for 
transfection, targets 5' 
frameshift. 
PfEAB165 PF3D7_0424300 C*A*AGAAAGAAAGAAAAACAAGC 
OL187 
Phosphorothoiate modified 
oligo. Product for 
transfection, targets 5' 
frameshift. 
PfEBA165 PF3D7_0424300 G*T*ACTCCCTTCTTTTTGTGC 
OL231 gRNA 3' frameshift.  Anneal to OL232. PfEAB165 PF3D7_0424300 ATTGAACATAAAGAGAAATTTCCAA 
OL232 gRNA 3' frameshift.  Anneal to OL231. PfEAB165 PF3D7_0424300 AAACTTGGAAATTTCTCTTTATGTT 
OL257 
Phosphorothoiate modified 
oligo. Product for 
transfection, targets 3' 
frameshift. 
PfEAB165 PF3D7_0424300 C*A*AGAGAAATTGATTTTGGCAGC 
OL258 
Phosphorothoiate modified 
oligo. Product for 
transfection, targets 3' 
frameshift. 
PfEBA165 PF3D7_0424300 G*T*TCAAGATACATATTCTCATGC 
OL293 Amplify PCR product for sequencing PfEAB165 PF3D7_0424300 TTAACCCTGATTTTGATGC 
OL271 Amplify PCR product for sequencing PfEAB165 PF3D7_0424300 TCTCTCCACATATCTTTACC 
OL265 qRT-PCR PfAMA1 PF3D7_1133400 CAGCTGCTGTCGCTGTATTA 
OL266 qRT-PCR PfAMA1 PF3D7_1133400 CCATAATCTTGTGGTTCATCCATTT 
OL307 qRT-PCR PfEBA165 PF3D7_0424300 AGGTGGCACACAAAGTAGTC 
OL308 qRT-PCR PfEBA165 PF3D7_0424300 CAGTGCTTGGATCTTCTCTACC 
OL315 qRT-PCR Pfcyp87 PF3D7_0510200 AAACGGGAGATCCTTCAGGT 
OL316 qRT-PCR Pfcyp87 PF3D7_0510200 AAGGACATGGGACAGTGGTT 
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